Investors & News

Posters & Publications

Title	Download
RANZCO 2024 presentation: A Phase 1 First-In-Human Study of VP-001 designed to treat Retinitis Pigmentosa type 11
ARVO 2024 presentation : A Peptide Conjugated Oligonucleotide for the Treatment of Retinitis Pigmentosa Type 11
VP-001 as an interventional therapy for patients with PRPF31 mutation-associated retinal dystrophy
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
RNA therapeutics in the treatment of retinal disease: delivering the potential
Enhancement of Antisense Oligomer Cell Penetration in Retinal Layers Using a Modular Cell Penetrating Peptide Platform
Modulation of CNOT3 expression using antisense oligomers to treat retinitis pigmentosa 11
GFP-complementation assay to detect functional CPP and protein delivery into living cells
Functional Disruption of a Disease Modifier Gene Using Antisense Oligomers: A Potential Molecular Therapy for PRPF31-associated Retinitis Pigmentosa 11
Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localisation and Disturb the Transcriptome In Vitro
Exploring microperimetry and autofluorescence endpoints for monitoring disease progression in PRPF31-associated retinopathy
Efficient Delivery of Antisense Oligonucleotides using Cell Penetrating Peptides Enables Potent, Durable Exon Skipping in Mouse and Human Disease Models
β-Lactamase Tools for Establishing Cell Internalization and Cytosolic Delivery of Cell Penetrating Peptides
A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery
Cell penetrating peptides for the delivery of ASOs to the neural retina across rodents and NHPs
PYC-001, a peptide-conjugated phosphorodiamidate morpholino oligomer for the treatment of autosomal dominant optic atrophy
PYC-001, a peptide-conjugated phosphorodiamidate morpholino oligomer for the treatment of autosomal dominant optic atrophy

Corporate Governance

PYC Therapeutics Limited (“Company”) has adopted a Corporate Governance Plan which forms the basis of a comprehensive system of control and accountability for the administration of corporate governance.

The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company’s needs.

To the extent they are applicable to the Company, the Board has adopted the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations 4th Edition (“Principles & Recommendations”).

A Corporate Governance Statement sets out details of the Company’s compliance with the Principles & Recommendations. Here is a link to the ASX Corporate Governance Principles & Recommendations.

The Company is pleased to make the following information on its corporate governance practices available on this website.

Title	Download
2024 Corporate Governance statement & 4G
CONSTITUTION – PYC THERAPEUTICS LIMITED
LONG TERM INCENTIVE PLAN RULES
LONG TERM INCENTIVE USA SUB PLAN

Charters

Title	Download
RISK COMMITTEE
REMUNERATION COMMITTEE
PYC NOMINATION-COMMITTEE- CHARTER
BOARD
AUDIT COMMITTEE

Policies and Procedures

Title	Download
Anti-Bribery & Anti-Corruption Policy
Corporate Code of Conduct
Definition of Independence
Continuous Disclosure Policy
Performance Evaluation Policy
Risk Management Policy
Diversity Policy
Shareholder Communications Policy
Share Trading Policy
Whistleblower Policy